1 / 6

Rixubis Market (Hemophilia A

The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.

fareeqrahal
Download Presentation

Rixubis Market (Hemophilia A

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Rixubis (Hemophilia A and B) – Forecast and Market Analysis to 2022byGlobalData Explore all reports for “Hematology Therapeutics” market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/hematology-therapeutics . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  2. Rixubis (Hemophilia A and B) – Forecast and Market Analysis to 2022 The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden. Baxter’s Rixubisis a recombinant Factor IX replacement therapy for prophylactic, on-demand and perioperative treatment of adults with severe hemophilia B. Rixubis, which received FDA approval in June 2013, is the only recombinant FIX replacement therapy indicated for prophylactic use in hemophilia B patients. Request sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=145256 . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  3. Rixubis (Hemophilia A and B) – Forecast and Market Analysis to 2022 Scope Overview of Hemophilia A and B, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Rixubis including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for Rixubis for the top nine countries from 2012 to 2022. Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Argentina and China. Complete report available @ http://www.rnrmarketresearch.com/rixubis-hemophilia-a-and-b-forecast-and-market-analysis-to-2022-market-report.html . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  4. Rixubis (Hemophilia A and B) – Forecast and Market Analysis to 2022 Reasons to buy Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and in-depth analysis of Rixubis performance Obtain sales forecast for Rixubis from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Argentina and China) Request sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=145256 . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  5. Rixubis (Hemophilia A and B) – Forecast and Market Analysis to 2022 Table of Contents 1 Table of Contents 41.1 List of Tables 6 2 Introduction 72.1 Catalyst 72.2 Related Reports 82.3 Upcoming Related Reports 10 3 Disease Overview 114 Disease Management 17 5 Competitive Assessment 22 6 Rixubis (BAX-326) 27 7 Appendix 31 Request sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=145256 . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  6. Rixubis (Hemophilia A and B) – Forecast and Market Analysis to 2022 For more details contact Mr. PriyankTiwari:sales@rnrmarketresearch.com/ +18883915441 RnR Market Research RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnR  Market Research library has syndicated reports by leading market research  publishers across the globe. © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

More Related